drugset / Trial / NCT03848832

Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

NCT03848832

Phase 3 Terminated 29 enrolled Jazz Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy of cannabidiol oral solution (GWP42003-P, CBD-OS) in reducing symptom severity when compared with placebo, in participants with Rett syndrome.

Timeline

Start
2019-07-29
Primary completion
2021-01-21
Completion
2021-01-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabidiol Other / unclassified 5 mg/kg Oral
Subject Cannabidiol Other / unclassified 15 mg/kg Oral